Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
Brief Summary: The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg
C: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: Part 1: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 3: Tildrakizumab 5 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 25 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 100 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 200 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Placebo Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: tildrakizumab; Assigned to Arm(s): Part 1: Tildrakizumab 100 mg, Part 1: Tildrakizumab 200 mg, Part 1: Tildrakizumab 25 mg, Part 1: Tildrakizumab 5 mg, Part 2: Tildrakizumab 100 mg, Part 2: Tildrakizumab 200 mg, Part 2: Tildrakizumab 25 mg, Part 2: Tildrakizumab 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo

Answer: C